本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
BEIJING, June 12, 2024 /PRNewswire/ -- In Beijing, the essay topic for the English test of this year's gaokao focuses on the 75th anniversary of the founding of the People's Republic of China. Chinese middle school student Li Hua is asked to offer some suggestions to his foreign friend Jim, who wants to write a piece on this subject. To help enlighten Jim as well as those who are interested in China's development, Global Times invited several foreign experts and observers to share their insights on China's great achievements in various spheres over the past seven and half decades. Discussing China's achievements over the 75 years since the founding of the People's Republic could be the subject of a very long book and is understood in different ways by different generations of people. I've always believed the best way to know how people in China think, is to ask them. So, through asking a range of different people from different generations we can expect to find a range of different answers. Those students who have been preparing all their school lives to take the recent gaokao, the "national college entrance examinations", had slightly different responses to those who took the exam in my early years of teaching here, around 2004 and 2005. For interest, I thought it might be good to get the opinions of some older Chinese people too, and so I asked a retired couple. Teenagers love connectivity, being able to communicate with family and friends and shop online with their phone. Interestingly, pensioners have similar views about mobile phones, the community they live in provides them with free classes that help them learn how to use WeChat so they aren't so disconnected from their grandchildren, especially during the school term. They learn about online shopping and banking; they know how to upload and download and they have courses on how to avoid internet and mobile scams. The youngsters don't need that, they seem to have an inherent understanding of how to be safe online. The retirees also think education is important. To them, this was the most important development in China, and the country is now strong because of it. China leads the world in science and technology and has more students enrolled in university courses than any other country in the world and the future is being built on a foundation of education. The youngsters agree, but for a different reason. School is better; they have modern classrooms, modern facilities, computerization and sports. Older people remember the rivers and how they used to play in them when they were kids. China's development, they say, came at an environmental cost which they paid the price for but that has changed in recent years. Strong anti-pollution rules and the introduction of electric cars and buses have all helped; the rivers are cleaner and the air is fresher. Transportation was most important to the middle group, these are young professionals with families of their own. To be able to get on a train in Guangdong and just a few hours later get off the train on the other side of the country means they can get to see their families, take holidays and have more time for themselves. One lady in her fifties described getting to university in the 1990s as a 16-hour bus trip with several ferry crossings. The journey now takes 27 minutes on the high-speed train and driving a car, something she would never have imagined in her younger days, takes her less than 90 minutes. She laughed when she said it takes her son less time to get to college in Australia than she took to travel 100 kilometers inside Guangdong. China's bridges have made this possible but it doesn't stop there. An interconnected system of freeways and bridges connects everywhere in China to everywhere else. And in talking about this, she realized there was another great achievement for China, the very fact that she now owns a car and is able to send her child to school overseas was unthinkable when she was her son's age. Everyone in China is better off than they were, and everyone I speak to is optimistic that they will continue along this trajectory. If you ask anyone of any age, any generation and from any background, what are China's two or three greatest achievements, some will say the internet connectivity, some will say transportation or infrastructure and some describe the health system which has consistently delivered better outcomes over the last 75 years and increased the life-expectancy to higher than that of most developed countries. Others talk of the education system that produces more STEM graduates than the US, Russia, the European Union and the UK combined, while some will say the de-desertification and the environmental improvements, bringing clean air and blue skies back to the cities. But they will all agree that the no.1 achievement is lifting the people out of poverty. The greatest achievement of any country is to do the right thing for its people. And in these 75 years, China has done exactly that.
Award acknowledges INEOS Styrolution's commitment to quality, reliable supply and exceptional customer service. Sichuan Changhong Electric leverages INEOS Styrolution's Styrolution® PS grade for its Meiling range of refrigerators. SHANGHAI, June 12, 2024 /PRNewswire/ -- INEOS Styrolution, the global leader in styrenics, received the 2024 Best Quality Supplier Award from Sichuan Changhong Electric, at the company's annual supplier conference held in Sichuan, China. Founded in 1958, Sichuan Changhong Electric is one of the top domestic home appliance brands in China. INEOS Styrolution's Styrolution® PS, a high impact, extrusion/thermoforming grade has been specified for the liner application of Sichuan Changhong Electric's Meiling range of refrigerators. This material possesses exceptional resistance to attack from fats and oils and is specifically designed to exhibit a high resistance to environmental stress cracking (ESCR), ideal for fridge liner application. Jui Seng Tay, President Asia Pacific, INEOS Styrolution, says "We are extremely delighted to receive this award from Sichuan Changhong Electric again[1], as it is an irrefutable affirmation of our commitment to deliver value and support for our customers' growth and success. We will strive to deepen our collaboration with Sichuan Changhong Electric, supporting their ambitious goals in the home appliance industry." Styrolution® PS impact modified polystyrene resins are a line of robust grades suitable for extrusion and injection molding, designed to fulfill a variety of customers' needs. Whether the application is intended for a single use yogurt cup or a durable refrigerator liner, Styrolution PS HIPS resins can meet the demands of technically challenging applications. [1] Read INEOS Styrolution receives Best supplier Award 2023 from Sichuan Changhong Electric ENDS About INEOS Styrolution INEOS Styrolution is the world's leading styrenics supplier, with a high-performing portfolio of styrene monomer, polystyrene, ABS and advanced styrenic products. With more than 90 years of innovation in materials science, INEOS Styrolution is focused on customer satisfaction with differentiated solutions that provide a competitive edge as well as investments in technology that enable closed loop recyclability for styrenics while reducing our carbon emissions. INEOS Styrolution applications can be found in many everyday products across multiple industries: including automotive, electronics, household, construction, healthcare, packaging, and toys/sports. Operating 17 production sites in nine countries, the company is a wholly owned subsidiary of INEOS Group Limited and employs approximately 3,000 people. Sales were 4.5 billion euros in 2023. www.ineos-styrolution.com Media contact Hui Boon Kwa huiboon.kwa [@] ineos.com mobile: +65 90038193
Comprised of the 21-Year-Old, Alongside New 25-Year-Old and 30-Year-Old Expressions, The Glasshouse Collection Celebrates the Exceptional Aging of The Glen Grant Whiskies ROTHES, Scotland, June 11, 2024 /PRNewswire/ -- The Glen Grant Single Malt Scotch Whisky, nestled in the heart of Speyside, today unveils The Glasshouse Collection: a new prestige range featuring the oldest aged expressions ever in the distillery's permanent collection. The Glen Grant 21-Year-Old is joined by The Glen Grant 25-Year-Old and 30-Year-Old Single Malt Scotch Whiskies to form a collection of rare single malts which celebrate the unparalleled aging of whiskies from the over 180-year-old distillery. THE GLEN GRANT UNVEILS "THE GLASSHOUSE COLLECTION": A NEW PRESTIGE RANGE FEATURING THE OLDEST AGED SINGLE MALT SCOTCH WHISKIES IN THE PERMANENT PORTFOLIO The Glasshouse Collection was born from the legacy of The Glen Grant's visionary forefather James 'The Major' Grant. An avid traveler, 'The Major' was a charismatic and eccentric innovator, voyaging to destinations around the world – from Southern Africa to the peaks of the Himalayas. With every adventure, he collected flowers and plants, bringing them back to Scotland and his vast Victorian-inspired glasshouse, built in 1886 to protect and nurture the most precious and delicate plants, just as the distillery's warehouses have done with these exquisite spirits for decades. This is the inspiration for The Glen Grant Glasshouse Collection, comprised of three rare single malt whiskies, created to capture the essence of The Major's Glasshouse. Each expression reflects a distinct time of day, from the first light of dawn until the moonlit night, using the light inside the glasshouse as a metaphor for the character of each exceptionally aged spirit. The launch of this new collection marks a significant milestone for The Glen Grant, as legendary Master Distiller Dennis Malcolm OBE approaches his retirement after over six decades in the Scotch whisky industry. The Glasshouse Collection will be the last whiskies to be released under Dennis' stewardship, but his legacy will be upheld and honoured by his successor Greig Stables, who has worked closely with Dennis over the last 18 years and played a pivotal role in the creation of the new collection. "Working alongside Dennis for nearly two decades has been an incredible journey and I'm deeply grateful for his insight and guidance," said Stables. "As I become Master Distiller, I carry with me the lessons learned and the guiding vision imparted on this journey. I'm honoured to lead The Glen Grant into this new chapter and am excited and enthused for what is to come. Now as we introduce these rare and aged whiskies, I am thrilled we can showcase how exceptionally The Glen Grant spirit ages over time, maintaining its character and integrity. In honour of the launch and the legacy of Dennis, I'd like to raise a toast to him with our Double Gold award winning 25-Year-Old." JOURNEY THROUGH THE GLASSHOUSE COLLECTION Each carefully aged prestige whisky in The Glasshouse Collection is matured in American oak bourbon barrels and Oloroso Sherry casks within the hallowed walls of the distillery's oldest traditional stone dunnage warehouse. Our signature taller-necked copper stills and water-cooling purifiers, which ensure that only the finest vapors are collected, create the distinct and delicate essence of zesty green apples for which The Glen Grant is known. The character of the three whiskies, 21-, 25-, and 30-Year-Old, represent a journey through the cycle of daylight within the Glasshouse and showcase the aging potential of The Glen Grant spirit. The Glen Grant 21-Year-Old represents the first light in the Glasshouse, capturing the delicate and ethereal quality of the early morning light. Just as the first light of day breathes life into the garden, this expression embodies a fresh and vibrant character with an explosion of tropical fruits, creamy butter notes, and an enduring crème brûlée finish define this single malt, transporting and immersing you in the light, with characterful flair. Bottled at 46% ABV, natural in color, and non-chill filtered, it encapsulates the evocative and aromatic warmth akin to the sun illuminating the day. As the light of golden hour casts its glow on the Glasshouse, a new offering from The Glen Grant, the distinguished 25-Year-Old, comes to life. Like the setting sun casting its warm glow, this whisky unveils itself with velvety smoothness. It encapsulates the essence of dried stone fruit and toffee notes, each sip revealing distinctly sweet aromas. Delve deeper, and uncover rich flavors of dark chocolate, zesty orange, oak, and nutmeg, culminating in a finish of warm spice with a subtle hint of soft smoke. With 25 years of aging and bottled at 46% ABV, natural in color, and non-chill filtered, this expression embodies the evocative and aromatic warmth reminiscent of the sun gently setting over the Glasshouse during the golden hour. Just as the last rays of daylight caress the landscape, this whisky captures the essence of lingering warmth and golden hues. As twilight descends upon us, we are transported to the Glasshouse bathed in moonlight, tranquil yet alive with movement of light and shadow. In this moment we discover The Glen Grant 30-Year-Old, rare and exquisite with a bouquet of rich, complex, oaky tones and deep, distinctive finish. Matured for thirty years, this rare and evocative whisky unfolds with intricate layers of oak, woven with hints of nectarine, honey, and dried fruit, evoking a sense of timeless indulgence. Each sip reveals the depth of its maturity, as flavors of demerara sugar and a velvety creaminess dance upon the palate, leading to an irresistibly sweet and fruity finish that lingers, leaving one yearning for more. Bottled at 48% ABV, natural in color, and non-chill filtered, 30-Year-Old welcomes the cool tones of moonlight as they wash over the Glasshouse. A DAY IN THE GLASSHOUSE: AN EXPLORATION OF LIGHT WITH LACHLAN TURCZANTo mark the launch of this historic release, The Glen Grant has partnered with artist Lachlan Turczan, to create a new installation titled "A Day in the Glasshouse" through his immersive series, 'Optical Resonance.' Turczan's innovative cymatic sculptures utilize light and water, a fundamental component of the distillation process, to create mesmerizing reflections. "A Day in the Glasshouse" is portrayed through three pieces, each reflecting the unique facets of a different whisky in the prestigious range. An ode to the individual age, character, and time of day associated with each spirit, this artistic partnership immerses enthusiasts in an experiential multi-sensory journey to heighten the tasting experience of each expression, beautifully aligning with The Glen Grant's commitment to taking inspiration from around the world. "My exploration of The Glen Grant Glasshouse Collection is rooted in my art practice exploring liquid light phenomena. I was inspired by the fascinating history of James 'The Major' Grant, whose travels and passion for preservation echo my own interests. With 'Optical Resonance,' I aimed to highlight the nuances of changing light throughout the day, paired with each whisky. From the gentle ripples of dawn embodied the 21-Year-Old to the mesmerizing cymatic patterns of the moonlit 30-Year-Old, my water and light sculptures offer an immersive sensory experience that invites enthusiasts to experience the confluence of art, science, and world-renowned whisky craftsmanship." AVAILABILITYThe Glasshouse Collection will be available in select markets worldwide, including the U.S, U.K., and Asia beginning in 2024. Joining the 21-Year-Old (RSP $360 USD), The Glen Grant 25-Year-Old will be available at an RSP of $1,000 USD and The Glen Grant 30-Year-Old at an RSP of $3,000 USD. For more information, please visit us at our website or follow us on Instagram @theglengrant. ABOUT THE GLEN GRANTBrothers James and John Grant built The Glen Grant in 1840, the first distillery in the town of Rothes in Speyside. They left a legacy of ingenuity by engineering the first northern railroad and introducing electric light to both the distillery and the entire town. In 1872, heir James 'The Major' Grant, a charismatic innovator and adventurous traveler, inherited the business. Through his intrepid journeys to destinations around the world, he made inspiring discoveries which led to the creation of his beloved 27-acre Garden of Splendours, the only distillery garden of its kind in Scotland. Inspired by his splendid garden, he envisioned a distinctive single malt, engineering tall, slender pot stills combined with unique water-cooling purifiers to create the evocative flavour profile that defines The Glen Grant Single Malt Scotch Whisky to this day. Now, it is our Master Distiller who honours the passionate spirit of The Glen Grant. The team at the Glen Grant, continues combining tradition and innovation to preserve the rare character of the whiskies, which are crafted from barley to bottle entirely on the distillery grounds, ultimately ensuring the utmost quality. ABOUT CAMPARI GROUP Campari Group is a major player in the global spirits industry, with a portfolio of over 50 premium and super premium brands, spreading across Global, Regional and Local priorities. Global Priorities, the Group's key focus, include Aperol, Campari, SKYY, Grand Marnier, Espolòn, Courvoisier, Wild Turkey and Appleton Estate. The Group was founded in 1860 and today is the sixth-largest player worldwide in the premium spirits industry. It has a global distribution reach, trading in over 190 nations around the world with leading positions in Europe and the Americas. Campari Group's growth strategy aims to combine organic growth through strong brand building and external growth via selective acquisitions of brands and businesses. Headquartered in Sesto San Giovanni, Italy, Campari Group operates in 23 production sites worldwide and has its own distribution network in 26 countries. Campari Group employs approximately 4,900 people. The shares of the parent company, Davide Campari-Milano N.V. (Reuters CPRI.MI - Bloomberg CPR IM), have been listed on the Italian Stock Exchange since 2001. For more information: http://www.camparigroup.com/en. Please enjoy our brands responsibly. THE GLEN GRANT UNVEILS "THE GLASSHOUSE COLLECTION": A NEW PRESTIGE RANGE FEATURING THE OLDEST AGED SINGLE MALT SCOTCH WHISKIES IN THE PERMANENT PORTFOLIO
Deakin University Lancaster University Indonesia opens its doors, offering students the chance to earn dual bachelor's degrees from two top-ranked universities. Indonesian students can access world-class qualifications while remaining close to family and friends. The university launches with five undergraduate programs in Business and IT, tailored to meet current and future job market needs. SINGAPORE, June 11, 2024 /PRNewswire/ -- In September 2024 a new University opens its doors in the thriving education hub of Bandung, West Java. Deakin University Lancaster University Indonesia is an innovative education partnership between two globally ranked universities that will offer new higher education opportunities to students from across Indonesia and around the world. This is not just any University. Through Deakin University Lancaster University Indonesia, students will be able to obtain a dual degree – one bachelor's degree from Deakin University in Australia and one bachelor's degree from Lancaster University in the UK – in up to just four years of study. All courses offered by Deakin University Lancaster University Indonesia have obtained approval of the Indonesian Government and are equivalent to a Sarjana degree from a local Indonesian university. "This is a unique opportunity for Indonesian students to obtain world-class qualifications from two globally ranked universities, while enjoying the many benefits of living and working close to home, supported by their families and friends," said the Deakin University Lancaster University Indonesia Chief Operating Officer, Prana Sudhana. Deakin University Lancaster University Indonesia will initially offer five undergraduate programs in the areas of Business and Information Technology (see below). Students will have multiple entry points to the dual-award bachelor degree programs, including direct entry, or through foundation studies that prepare them for entry into their first year of degree study. Academic English courses are also available from April 2025 to prepare students for successful undergraduate study. "Deakin University and Lancaster University both rank among the top 1% of universities globally," said Mr Sudhana. "With extensive experience in two-way exchanges, study tours, and work-integrated learning, these institutions also provide a unique opportunity for students to study abroad for a semester at either or both universities in Australia and the UK. "Graduates will earn highly respected qualifications that pave the way for global career success, along with exceptional student experiences that support their personal and professional growth." The Deakin University Lancaster University Indonesia campus will be centrally located in a vibrant part of Bandung, approximately one hour by high-speed train from Jakarta. Work is currently underway to transform the building into a world-class university for students and staff. Bachelor of Business Analytics + BSc Hons Business Analytics Students will embark on a transformative dual degree that integrates 50% of modules from Deakin University's Bachelor of Business Analytics and 50% from Lancaster University's BSc Business Analytics. Developed with input from industry leaders, including IBM, Deloitte, and PwC, this dual degree is designed to meet current and future business needs, with an emphasis on project management, idea implementation and employee support. Bachelor of Commerce + BSc Hons Business Management Tailored for aspiring professionals, this programme integrates 50% of modules from each university, providing a well-rounded and industry-relevant education. Students will develop skills and expertise for a successful career in global business, with emphasis on critical areas such accounting, economics and finance. This dual degree provides Indonesian students with in-country access to a business-related degree – the most popular choice of study for Indonesians studying in the United Kingdom. It is uniquely designed by two AACSB and EQUIS accredited business schools. Bachelor of Commerce + BSc Hons Accounting & Finance This combined degree blends tradition with contemporary approaches to help students discover their professional calling in disciplines such as accounting, economics, finance and more. Alumni of both undergraduate programmes across Deakin University and Lancaster University have successfully ventured into roles with large accounting firms, international consulting firms, corporations, and global banks. The programme is designed in the UK and Australia to comply with national accounting accreditation requirements. IT Dual Degrees Bachelor of Computer Science + BSc Hons Computer Science Step into one of the most exciting and dynamic industries with a dual degree that integrates 50% of modules from Deakin University's Bachelor of Computer Science and 50% from Lancaster University's BSc Hons Computer Science. From data analytics to robotics to intelligence, this course is broad but rigorous enough to set students up for career success. The dual degree is a STEM-aligned program originally designed in the UK and Australia to comply with national computing society accreditation requirements. It is a cutting-edge undergraduate degree program supported by modern equipment, geared towards students who want to make a positive change in the world. Bachelor of Cyber Security + BSc Hons Computer Science This dual degree, designed to support career success in a rapidly evolving and critical sector, integrates 50% of modules from Deakin University's Bachelor of Cyber Security and 50% from Lancaster University's BSc Hons Computer Science. Students will learn everything it takes to become a future-proofed computing professional, with a specialisation in cyber security and deep knowledge in areas such as digital forensics and computer crime. This STEM-aligned program was designed in the UK and Australia to comply with national computing society accreditation requirements. For more information about Deakin University Lancaster University Indonesia visit www.dli.ac.id
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) of China's National Medical Product Administration (NMPA) has approved a global registrational Phase III study of the company's novel drug candidate olverembatinib (HQP1351), in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) who had failed prior systemic treatment. This approval marks a major milestone in Ascentage Pharma's clinical development in solid tumors. This global, multicenter, single-arm, open-label, pivotal registrational Phase III study is designed to evaluate the efficacy and safety of olverembatinib in patients with SDH-deficient GIST. The CDE has agreed that results from the study can be used to support a future New Drug Application (NDA) for olverembatinib in SDH-GIST. GIST is the most common type of soft tissue sarcoma that arises in the gastrointestinal track, with a global incidence of 1-1.5/100,000 per year.1 KIT and PDGFRA are key genetic drivers of GIST, and 85% - 90% of all patients with GIST harbor KIT or PDGFRA mutations. The introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with this subset of GIST. However, 85% of pediatric patients and 10%-15% of adult patients with GIST do not harbor KIT or PDGFRA mutations, thus belong to a subtype dubbed wild-type GIST. Depending on whether the SDH expression is lost in the patient, wide-type GIST can be further categorized into SDH-deficient and non-SDH-deficient GISTs.2-3 SDH-deficient GIST has unique clinical and pathological characteristics. According to existing literatures, SDH-deficient GIST has a median age of diagnosis of 21 years and is more common in women. SDH-deficient GIST, primarily arises in the gastric area with a high propensity to metastasize, is characterized in immunohistochemistry essays by the loss of SDHB protein expression. Patients with early-stage localized SDH-deficient GIST can be treated with surgeries, although most patients eventually relapse. At present, there is no standard treatment option for relapsed and advanced SDH-deficient GISTs. Imatinib is generally considered ineffective for the condition and other TKIs have also failed to demonstrate satisfactory efficacy2-5, offering a five-year event-free survival (EFS) rate of just 24%.4 Being commonly diagnosed at young ages, patients with SDH-deficient GIST endure significant impact on their quality of life and survival, therefore have urgent unmet medical needs for new treatment options. Olverembatinib is an orally-available novel third-generation TKI developed by Ascentage Pharma. The drug has been granted a Breakthrough Therapy Designation by the China CDE for the treatment of patients with SDH-deficient GIST who had received first-line treatment. As a multi-targeted TKI, olverembatinib has shown excellent efficacy and manageable safety in patients with SDH-deficient GIST. Since 2022, the clinical study evaluating olverembatinib in SDH-deficient GIST has been selected for presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting for three consecutive years, including an oral report at the 60th ASCO Annual Meeting just took place this month. According to the latest results, olverembatinib has achieved a clinical benefit rate (CBR) of 92.3% in patients with SDH-deficient GIST. Olverembatinib is the first China-approved third-generation BCR-ABL inhibitor. To date, the drug has been approved for two indications in China, including adult patients with TKI-resistant chronic-phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP) harboring the T315I mutation; and adult patients with CML-CP resistant to and/or intolerant of first-and second-generation TKIs. Olverembatinib is jointly commercialized in China by Ascentage Pharma and Innovent Biologics. "In earlier studies, olverembatinib has already shown encouraging efficacy and favorable safety in patients with SDH-deficient GIST," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "We are excited by the approval for this global registrational Phase III study because it could potentially lead to a clinical breakthrough for another indication that currently lacks approved treatment options while marking a major milestone for Ascentage Pharma's clinical development in solid tumors. Remaining steadfastly committed to the mission of addressing unmet clinical needs in China and around the world, we will expeditiously advance this clinical development program for the benefit of more patients." References Mantese G. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol. 2019; 35(6): 555-559. Call JW, Wang Y, Rothschild S, et al. Treatment responses in SDH-deficient GIST. LRG Science, https://liferaftgroup.org/2019/08/treatmentresponses-in-sdh-deficient-gist-2/(2019, accessed 4 May 2022). Nannini M, Rizzo A, Indio V, et al. Targeted therapy in SDH-deficient GIST. Ther Adv Med Oncol. 2021; 13: 17588359211023278. Weldon CB, Madenci AL, Boikos SA, et al. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017; 35(5): 523-528. Mullassery D, Weldon CB. Pediatric/"Wildtype" gastrointestinal stromal tumors. Semin Pediatr Surg. 2016; 25(5): 305-310. *Olverembatinib is an investigational drug that has not been approved for any indication outside the Chinese mainland. About Ascentage PharmaAscentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK. Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials, including 6 global registrational phase III studies, in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases. Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product in China, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients. Forward-Looking StatementsThe forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.
SAN DIEGO and IRVINE, Calif. and HONG KONG, June 11, 2024 /PRNewswire/ -- On June 11, the President of the Reproductive Science Medical Center (RSMC) in the United States successfully concluded his visit to Asia. During the week-long trip, the President engaged in one-on-one meetings with guests from various regions, providing in-depth explanations of reproductive technologies and treatment options. This visit covered multiple regions, including Hong Kong, Taipei, Shanghai, and Tokyo, attracting many couples, singles for consultations. The openness of U.S. laws compared to those in Asia, along with Taiwan's leading position in IVF technology, has made Taiwan a pivotal intermediary for IVF in Asia. Unlike Hong Kong, where frozen eggs can only be stored for ten years, or Hong Kong, Japan, and Singapore, where there are many restrictions on PGS genetic screening, Taiwan offers more flexibility. Many clients choose to freeze their sperm, eggs, and embryos in Taiwan and then legally transport them to the U.S., where IVF treatments are not restricted by marital status or sexual orientation, fulfilling their dreams of parenthood. From a business perspective, this visit not only strengthened RSMC's connections with Asian clients but also highlighted the global development of the reproductive industry chain. Those in need of fertility services can choose the appropriate country based on their identity, budget, reproductive plans, and geographic location, piecing together their fertility journey like assembling components. As the final destination for many of these journeys, the U.S., particularly RSMC in California, with its 30 years of clinical experience and multilingual, round-the-clock one-stop services, has become the top choice for many Asian clients. To date, RSMC has helped over 20,000 families achieve their fertility dreams. If you are interested, please visit our website or schedule a free online consultation with the American President. English Website | Traditional Chinese Website | Simplified Chinese Website |Japanese Website Contact us Line: rsmctw WhatsApp: +1 858-342-6046 Wechat: rsmctw Email: rsmctw@fertile.com.hk
A12 藝術空間
Science
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
